Aviir, Inc. Leadership

Dr. Tabibiazar is a seasoned executive with leadership experience in healthcare and biopharma industry that included venture capital, pharmaceutical, diagnostics, and life sciences. As a clinician-entrepreneur his efforts have focused on creating new ventures in form of new companies or spin-outs to translate innovative science into commercially viable products. Through his venture capital and finance experience at a large Venture Capital firm, he has also been involved in evaluation and management of novel technologies and investment opportunities. Prior to moving to the industry, Dr. Tabibiazar was a practicing cardiologist and an adjunct faculty at Stanford University having trained as a physician scientist at Harvard Medical School and a cardiologist at Stanford Medical Center.

Cynthia French joined Aviir in November 2010 as Chief Scientific Officer and is responsible for R&D, product development, and clinical laboratory operations. Before Aviir, she served as Chief Scientific Officer as well as Executive in Charge of Clinical Laboratory Operations for both Denmark and California sites at Exiqon. She has been directly involved in product development of new molecular diagnostics in the microRNA, DNA, and proteomics fields. Prior to Exiqon, Cynthia served as Vice President, Affymetrix Clinical Laboratory Services, and was responsible for commercialization of CLIA laboratory operations - offering Affymetrix microarrays for genetic and molecular expression diagnostic testing. She has also held executive positions at Specialty Diagnostics, Quest Diagnostics, and Bio-Rad Laboratories. Cynthia has extensive experience in managing product development, CLIA laboratory operations and clinical trials in both life sciences and diagnostics industries worldwide. Cynthia received her PhD and MBA from the University of California, Irvine, and she was a postdoctoral fellow at MIT and Harvard University.

Dr. Tabibiazar is a seasoned executive with leadership experience in healthcare and biopharma industry that included venture capital, pharmaceutical, diagnostics, and life sciences. As a clinician-entrepreneur his efforts have focused on creating new ventures in form of new companies or spin-outs to translate innovative science into commercially viable products. Through his venture capital and finance experience at a large Venture Capital firm, he has also been involved in evaluation and management of novel technologies and investment opportunities. Prior to moving to the industry, Dr. Tabibiazar was a practicing cardiologist and an adjunct faculty at Stanford University having trained as a physician scientist at Harvard Medical School and a cardiologist at Stanford Medical Center.